Focused On-demand Library for Small ribosomal subunit protein uS10m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P82664

UPID:

RT10_HUMAN

Alternative names:

28S ribosomal protein S10, mitochondrial

Alternative UPACC:

P82664; B2RE89; Q9H3E5; Q9NVR3

Background:

The Small ribosomal subunit protein uS10m, also known as 28S ribosomal protein S10, mitochondrial, plays a crucial role in the mitochondrial ribosome. It is involved in the translation of mitochondrial DNA-encoded proteins, essential for mitochondrial function and energy production. Its unique position in the ribosome makes it a key player in the synthesis of proteins that are critical for cellular respiration and energy conversion.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein uS10m could open doors to potential therapeutic strategies. Its pivotal function in protein synthesis within mitochondria suggests that targeting this protein could lead to novel treatments for diseases related to mitochondrial dysfunction.